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Translational Relevance
Tumor-infiltrating lymphocytes (TILs) in pre-treatment biopsies are associated with lower mortality in triple-negative breast cancer (TNBC). We investigated whether higher peripheral lymphocyte counts are associated with lower breast cancer-specific mortality (BCM) and overall mortatlity (OM) in TNBC. On multivariable analysis, we found that higher minimum absolute lymphocyte count, but not absolute neutrophil count, predicted improved OM and BCM. Fiveyear probability of BCM was 15% for patients who were ever lymphopenic versus 4% for those who were not. An exploratory analysis (N=70) showed a significant association between TILs and higher peripheral lymphocyte counts during neoadjuvant chemotherapy. The results contribute to an emerging understanding of immune function in TNBC. In future clinical trials for TNBC, peripheral lymphocyte counts should be explored in connection with TILs as a potential biomarker for treatment efficacy and cancer mortality. 
Introduction
Many factors influence breast cancer patients' risk of death, including age and comorbid conditions, tumor subtype, grade and stage, and treatments received. Prior studies have shown that lymphopenia, or a low peripheral blood lymphocyte count, may also be a harbinger of worse mortality from advanced carcinomas, sarcomas and lymphomas (1) (2) (3) (4) (5) (6) (7) . An association between lymphopenia and poor mortality outcomes in breast cancer was reported in 1976 (4) and later confirmed in two studies showing an associated risk of recurrence after primary surgery and neoadjuvant therapy (5, 7) . Several recent studies have demonstrated lower breast cancerspecific mortality associated with tumor-infiltrating lymphocytes (TILs) in patients treated with neoadjuvant/adjuvant chemotherapy. This is particularly notable with triple-negative breast cancer (TNBC) (8) (9) (10) (11) (12) , the breast cancer subtype that is defined by a lack of estrogen and progesterone receptor expression and of HER2 receptor over-amplification and has relatively high mortality (13) .
Emerging immune checkpoint inhibitors, particularly antibodies against programmed death receptor 1 (PD-1) and its ligand (PD-L1) (14) (15) (16) (17) , have shown promising results across cancer types, including in early-phase clinical trials among TNBC patients (16) (17) (18) (19) . Given this evolving therapeutic area, we investigated whether peripheral lymphocyte levels as measured by absolute lymphocyte count (ALC) have a similar prognostic effect as TILs in TNBC (8) (9) (10) (11) (12) . We took advantage of the Oncoshare database, which integrates electronic medical records (EMRs) of two Northern California healthcare systems with records of the California Cancer Registry (CCR, a contributing registry of the Surveillance, Epidemiology and End Results [SEER] program (20) ), to evaluate the following three aims; 1) factors associated with lymphopenia, 2)
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the association between ALC and mortality, and 3) the variation in strength of association between ALC and mortality over time among patients diagnosed with early-stage TNBC from 2000-2014. As a secondary exploratory analysis, we evaluated the relationship between peripheral blood lymphocytes and TILs among 70 patients with pre-treatment TIL information.
Methods
Oncoshare Data Resource
Data were collected using Oncoshare, a breast cancer outcomes research database that integrates EMR data from breast cancer patients treated at Stanford University Hospital and/or the community-based Palo Alto Medical Foundation (20, 21 ). Oncoshare links patient-level clinical data from EMRs to population-based CCR (SEER) data (22-24). The CCR, with mandated statewide reporting, provides a gold standard for patient identification, cancer staging and longterm follow-up. Methods involved in developing Oncoshare, including validation of the data linkage approach, have been published (20, 21) . In brief, clinical data from the two healthcare systems were extracted from EMRs, and drug data elements and laboratory results from EMRs were mapped to a standardized lexicon (25) . CCR records were requested for all patients with breast cancer treated at either of the two healthcare systems. Data from EMRs and CCR were then linked on an individual patient level and de-identified before research use. 
Variable Definitions and Sources
Variables from the CCR included age and race/ethnicity; cancer stage, grade,
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on March 28, 2018. © 2018 American Association for Cancer clincancerres.aacrjournals.org Downloaded from 9 estrogen/progesterone receptor (ER/PR), and HER2 status; and summary of initial treatment course, including surgery, neoadjuvant/adjuvant chemotherapy, and radiation therapy, administered by any treating institution in California. TNBC was defined as breast cancer that had no ER/PR staining using immunohistochemistry and no overexpression or amplification of HER2. Breast cancer-specific mortality (BCM) and overall mortality (OM) data were derived from the CCR, which collects this information using routine linkages with the Social Security Death Master File, the Registry of Motor Vehicles, and other national databases (26). OM was defined as the time from breast cancer diagnosis to death for any reason or the day of last followup. BCM was defined as the time from breast cancer diagnosis to breast cancer-specific death or the day of last follow-up. Neighborhood socioeconomic status (nSES, at the Census block-group level and in terms of statewide quintiles) was assigned based on Census data using the validated Yost index (27).
EMR data included receipt of neoadjuvant/adjuvant chemotherapy and radiation therapy and laboratory values. Ever lymphopenic was defined as having an ALC <1 K/µL, and ever neutropenic as having an absolute neutrophil count (ANC) <1 K/µL, anytime after TNBC diagnosis. Minimum ALC was defined as the lowest value of all reported ALC measures anytime after TNBC diagnosis. If a patient had only one ALC value measured, then it was set as the minimum. Minimum percent lymphocyte count was included as an additional measure of lymphopenia.
Germline BRCA1 and BRCA2 (BRCA1/2) mutation status (tested and positive for a deleterious mutation; tested and negative for a deleterious mutation; tested and had a variant of uncertain 
Inclusion and Exclusion Criteria
All patients in the Oncoshare database diagnosed with stages I-III TNBC between January 2000 and May 2014 were eligible. To restrict consideration of neoadjuvant/adjuvant chemotherapy to treatment which was undertaken for curative intent rather than for metastatic cancer, the chemotherapy receipt variable was limited to within one year of the initial breast cancer diagnosis. Patients were followed through May 31, 2014.
Exploratory Analysis of TILs and Peripheral Blood Lymphocytes
In an exploratory analysis of 70 patients who participated in a Phase II clinical trial of 
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nSES, race/ethnicity, BRCA1/2 mutation status (positive for a deleterious mutation; negative for a deleterious mutation and/or having a VUS, the latter two of which were combined as a single category given their similar clinical management; untested or unknown), age at diagnosis, and ever neutropenic. Odds ratios (OR) and 95% confidence intervals (CIs) were estimated.
Multivariable Cox regression models were fit to examine the association between minimum ALC and OM, and minimum ALC and BCM, adjusting for all covariates described above. Data from patients who were alive through the last follow-up date were censored. Hazard ratios (HR) and 95% CIs were computed. To determine five-year survival and the 95% confidence limits among ever-and never-lymphopenic patients, the survest function from the rms package in R was implemented using estimates from our fitted models and the mean and mode values for each of the continuous or categorical predictors, respectively (31) . For models that adjusted for additional covariates, primary analyses used a complete case approach, excluding patients with missing data. Given the high rate of patients without germline BRCA1/2 testing or reported ALC values, multiple imputation methods were implemented using the default settings of the MICE package in R (32), with five imputations used (33, 34). As a sensitivity analysis on using minimum ALC to measure lymphopenia, multivariable Cox regression models were fit, replacing minimum ALC with minimum percent lymphocyte count and adjusting for the covariates described above.
We used mixed effects logistic regression techniques to evaluate the association between mortality outcomes and time-varying ALC. All ALC values within each time interval were included. The two outcomes were indicators for whether or not OM or BCM occurred. The 12 models included time since diagnosis, time-varying ALC value, and their interaction (representing how the magnitude of association between ALC and mortality varied over time). A subject-specific random effect was included to account for correlation of observations within a given patient over time. In order to report the effect of ALC on mortality by years since diagnosis, we calculated contrasts from the interaction term for year 1 through year 6. Due to convergence issues, no other covariates were included in these models. OM and BCM for everlymphopenic and never-lymphopenic patients were displayed using Kaplan-Meier curves. For the exploratory analysis of baseline TILs and peripheral lymphocyte counts, we used the Spearman rank correlation test and reported the associated p-value and Spearman's rho. We performed all statistical analyses in R (Version 3.2.2, Vienna, Austria). All tests were two-sided and statistical significance used an alpha threshold of 0.05.
Results
Patient Characteristics
From January 1, 2000 through May 31, 2014, 1,463 patients were diagnosed with stages I-III TNBC and treated at Stanford University Hospital and/or Palo Alto Medical Foundation (Supplemental Figure 1) . Mean age at diagnosis was 54 years and most were non-Hispanic (NH) white (72%), followed by NH Asian/Pacific Islander (14%). Most were of the secondhighest nSES quintile. Nearly half (49%) had Stage II and three-quarters had high-grade disease (73%). Three-quarters received either adjuvant or neoadjuvant chemotherapy (76%) and approximately half (46%) received adjuvant radiotherapy. Nearly one-quarter (23%) were tested clinically for BRCA1/2 mutations, of whom 80 (24% of tested patients) carried a deleterious mutation in either or both genes. Most (81%) were never neutropenic (ANC <1.0 K/µL), yet 13 most (63.4%) were lymphopenic (ALC <1.0 K/µL) with a mean minimum ALC value of 0.9 K/µL ( Table 1) .
Over a median follow-up time of 4.5 years, 352 (24%) patients died, with 222 (63%) of these deaths from breast cancer. Approximately half (759, 52%) had at least one ALC value reported.
In comparison to the full cohort, those with ALC values were slightly more likely to receive neoadjuvant/adjuvant chemotherapy (81% versus 76%) and BRCA1/2 testing (29% versus 23%, Table 1 ).
Factors Associated with Lymphopenia
On our primary multivariable analysis, which only included variables that did not vary with time, higher stage was positively associated with lymphopenia (OR: 1.84, 95% CI: 1.03-3.28) ( Table 1 ).
Minimum ALC, OM and BCM
The number of reported ALC values ranged from 1-117 (mean 14, median 10). No significant difference in OM or BCM was observed between patients who had <10 (the median), versus ≥10 Figure 1) . The model predicted an absolute probability of five-year BCM among ever-lymphopenic patients of 15%, compared to 4% for never-lymphopenic patients (95% CI: 12%-17% for ever-lymphopenic patients versus 95% CI: 1%-6% for never-lymphopenic patients).
We observed no interaction between carriage of deleterious BRCA1/2 mutations and minimum ALC in a complete case analysis (HR: 0.58, CI: 0.30-1.09, Supplemental Table 2 ). Given the high number of missing values (77% of patients untested for BRCA1/2, 48% without reported ALC), we conducted a multivariable Cox regression analyses using multiple imputation of BRCA1/2 values in the cohort that was used in the complete case analysis (n=759). Results were unchanged with multiple imputation (Supplemental Table 3 ).
ALC, OM and BCM over Time
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Furthermore, temporal analyses for the radiotherapy and neutropenia variables were performed and showed that having radiotherapy after having a minimum ALC measurement (versus not having radiotherapy) was significantly associated with reduced mortality (HR: 0.02, 95% CI: 0.05, 0.30), whereas radiotherapy before a minimum ALC value (vs. no radiotherapy) was not significantly associated with mortality. There was no evidence to suggest that the timing of neutropenia relative to the timing of the minimum ALC measurement had a protective effect (Supplemental Tables 4-7) . clinical trial patients with both TIL and response data available showed no significant association between minimum ALC value (p=0.62) or ever having lymphopenia (p=0.53) and achieving pCR to neoadjuvant chemotherapy (data not shown).
Exploratory Analysis of TILs, ALC and Other Lymphocyte Counts
Sensitivity Analysis
Of 532 patients with percent lymphocyte counts available, higher percent lymphocyte counts were associated with lower BCM and OM (HR: 0.91, 95% CI: 0.88-0.95, and HR: 0.92, 95% CI: 0.89-0.94, respectively; Supplemental Tables 8 and 9 ). Since more patients had ALC data available (n=747, compared to 532 with percent lymphocyte count data), we present the ALC analysis primarily. To investigate the possibility that metastatic recurrence (and subsequent chemotherapy) caused the observed association between higher lymphocyte counts and lower mortality, we restricted ALC values to the first year post-diagnosis, when metastatic recurrence is rare. We observed the same inverse association of minimum ALC with BCM and OM when we restricted ALC values to the first year post-diagnosis, which offers evidence that a low ALC due to treatment of metastatic recurrence does not explain the observed finding of higher BCM and OM. Furthermore, we defined the term 'pre-chemotherapy' ALC as an ALC value measured within three months of breast cancer diagnosis. We found the same inverse association of minimum ALC with OM but not with BCM with this restricted sample size (512 patients had a baseline measure of ALC within the first three months of diagnosis, and 29 patients [6%] met the criteria of lymphopenia [ALC <1.0 K/µL]) (Supplemental Figures 4-6) . In order to address the temporal relationship between laboratory measures and neoadjuvant/adjuvant chemotherapy receipt, we created indicator variables in our survival models for the time order of ALC and 
Discussion
We found that peripheral ALC post-diagnosis was a strong predictor of BCM and OM among a large cohort of patients with stages I-III TNBC. Notably, this inverse association between ALC and mortality appeared to strengthen over time: in the sixth year post-diagnosis, there was an absolute difference of >10% in BCM among ever-lymphopenic versus never-lymphopenic TNBC patients (15% and 4%, respectively). The increasing separation of mortality curves over time might be consistent with an immune effect that enhances response to initial therapy of TNBC. Moreover, in a cohort of TNBC patients treated on a prospective clinical trial with available TIL data, there was a direct correlation between higher TILs and higher peripheral lymphocyte counts during neoadjuvant chemotherapy.
To our knowledge, this is the first study to demonstrate a significant inverse association between peripheral lymphocyte counts and cancer-specific mortality in patients with potentially curable TNBC. Among breast cancer subtypes, TNBC has the worst prognosis, yet also the strongest evidence for an effect of TILs on survival (9, 11, 12). Two recent studies showed that with every 10% increase in stromal TILs there was an associated reduction in the risk of TNBC relapse or death (35). Taken together with recent TIL studies, the present results strengthen the case for ongoing trials of PD-1, PDL-1 and other immunotherapies in TNBC (16, 19) . Furthermore, this study raises the question as to whether strategies to protect lymphocytes from chemotherapy in the adjuvant setting might be beneficial. On multivariable analysis, the main predictor of This study adds a piece to the intriguing puzzle of how the immune system mediates treatment response and cure in TNBC. Immuno-editing, the concept of tumor recognition by the host immune system, host protection against the tumor, and tumor escape (36-38), has garnered more recognition with recent advances in immunotherapy (14) (15) (16) (17) . It is increasingly evident that therapy-associated lymphocyte depletion in breast cancer patients can be associated with opportunistic infections, such as pneumocystis carinii pneumonia (39-41), similar to other immunocompromised hosts, such as those on long-term corticosteroid use or with acquired immunodeficiency syndrome (42) (43) (44) (45) . One emerging theory is that tumors with greater mutational burden are more immunogenic and thus respond better to drugs that target the interplay between host and tumor immune responses (15, 46) . Most TNBCs have basal-like subtype on gene expression profiling and high histologic grade, possibly denoting greater genomic instability in comparison to hormone receptor-positive breast cancers (13, 47) .
Furthermore, approximately 20% of TNBC patients have a deleterious germline BRCA1/2 mutation, which is an inherited defect in DNA double-strand repair that causes tumor genomic instability (48, 49) . One-quarter of tested patients in the present study carried a BRCA1/2 mutation, but we did not observe a significant interaction between BRCA1/2 mutations and ALC on mortality. However, this null result might relate to low genetic testing rates in this 2000-2014 diagnosis cohort: more than 70% were untested according to Myriad Genetics, the only laboratory that provided clinical BRCA1/2 testing during most of the study period. The low Aspects of this study warrant consideration. Limitations include its retrospective design and restrictions inherent to using clinical information that was not originally collected for research purposes, notably missing data. In particular, we cannot rule out the possibility that patients with poorer prognosis more often had blood counts measured. However, it is reassuring that low ANC was not associated with higher mortality, suggesting that the observed results are lymphocytespecific. Furthermore, a sensitivity analysis restricted to ALC values measured within the first year post-diagnosis (a time period before most metastatic recurrences) showed consistent associations with OM and BCM. We addressed missing data using multiple imputation methods, 
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between radiotherapy and minimum ALC measurements warrant further study, specifically evaluating the duration of lymphopenia, which we were unable to do using our current data source. Furthermore, additional research elucidating the temporal relationship between chemotherapy, radiotherapy and lymphopenia is warranted to understand the range of determinants associated with these findings. As with any observational study, causality inferred from associations can be misleading due to uncontrolled selection bias or confounding. While provocative, the correlation we observed between TILs and lymphocyte counts during neoadjuvant therapy is derived from an exploratory analysis, and thus must be considered hypothesis-generating only. This study's limitations are offset by its considerable strengths: the large number of TNBC patients (>1,400); long-term, highly complete mortality data available through SEER database linkage; detailed laboratory results available from EMRs and a genetic testing laboratory; and the real-world scope of more than one healthcare system, including an academic referral center and a community-based, multi-site practice.
In summary, we report a substantial, specific and lasting inverse association between peripheral lymphocyte counts and cancer-specific and overall mortality among women with potentially curable TNBC. These results add to an emerging understanding of immune function in TNBC. In future clinical trials for TNBC, peripheral lymphocyte counts should be explored in connection with TILs as a potential biomarker for treatment efficacy and survival. Research. Table 1 . Patient demographics for all patients and for the subset with a reported absolute lymphocyte count (ALC) at any time after breast cancer diagnosis Table 5 . Unadjusted association between absolute lymphocyte count (ALC), time in years since breast cancer diagnosis, and overall and breast cancer-specific mortality
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Figure 1.
Note: Drop in never-lymphopenic overall survival is due to death of the patient with the longest follow up time. The shaded areas represent the confidence intervals for each curve.
